Ascendis Pharma A/S Ordinary Share (ASND)
ASND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/0001193125-26-046590-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ASND on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | 2015 |
| SEC CIK | 0001612042 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | G7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $806.2M |
| Net income | -$255.3M |
| Operating income | Not in SEC XBRL data |
| Net margin | -31.7% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 18.2× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-09-20 |
| Latest annual report | 20-F | 2026-02-11 |
| Latest quarterly / interim | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 793 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.7% |
| 1 month | -5.4% |
| 3 months | -12.7% |
| Year to date | +6.3% |
| 1 year | +8.8% |
| From 52-week high | -18.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $210.39 | -2.93% | $13.7B |
| CORT | Corcept Therapeutics Incorporated | $117.80 | -2.80% | $12.7B |
| SMMT | Summit Therapeutics Inc. Common Stock | $15.52 | -9.40% | $12.4B |
| BBIO | BridgeBio Pharma Inc. | $63.30 | -3.73% | $12.4B |
| ELAN | Elanco Animal Health Incorporated | $22.41 | -0.67% | $11.2B |
| VTRS | Viatris Inc. | $17.25 | -1.65% | $19.8B |
| RDY | Dr. Reddy's Laboratories Ltd | $12.77 | -0.39% | $10.7B |
| BMRN | BioMarin Pharmaceutical Inc. | $54.38 | -1.82% | $10.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier